Search results
BioNTech Cancer Drug Licensed From MediLink Faces FDA Delay
Bloomberg via Yahoo Finance· 10 hours ago(Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an...
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug
Reuters· 11 hours ago, opens new tab on Monday the U.S. Food and Drug Administration has placed a partial clinical hold...
FDA halts trial of BioNTech-MediLink ADC over 'significant risk of illness'
FierceBiotech· 13 hours agoThe FDA has slammed the brakes on MediLink Therapeutics’ trial of a BioNTech-partnered antibody-drug...
Kansas sues Pfizer over 'misrepresentations' and 'adverse events' of COVID-19 vaccine
FOX Business· 11 hours agoThe State of Kansas has filed a lawsuit against Pfizer, Inc. for alleged consumer protection...
BioNTech SE (NASDAQ:BNTX) Shares Purchased by PARUS FINANCE UK Ltd
ETF DAILY NEWS· 3 days agoPARUS FINANCE UK Ltd increased its stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 1.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 25,974 ...
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
Reuters via Yahoo Finance· 7 hours agoThe U.S. state of Kansas on Monday sued Pfizer, accusing the company of misleading the public about...
BioNTech (NASDAQ:BNTX) Receives “Buy” Rating from HC Wainwright
ETF DAILY NEWS· 7 days agoHC Wainwright reissued their buy rating on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Monday, Benzinga reports. The brokerage currently has a $113.00 ...
Kansas attorney general sues Pfizer over COVID vaccine, company responds
KSNT Topeka· 9 hours agoRelated video: Class action lawsuits – what are they, and should you join one? TOPEKA (KSNT) –...
Gateway - The Root
The Root· 4 hours agoThe Biden administration is expected to announce this week that Americans who got the Pfizer-BioNTech or Moderna vaccines will need the third shot to protect themselves against ...
Moderna stock is lone omen of bird flu pandemic
Reuters· 7 hours agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...